Peak inspiratory flow rates through placebo dry powder inhaler device in various asthma and COPD patients Source: Annual Congress 2012 - Asthma management Year: 2012
Peak inspiratory flow in patients with moderate or severe COPD using the Almirall inhaler Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Peak inspiratory flow rates in COPD patients with Easyhaler® dry powder inhaler Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Peak inspiratory flow (PIF) when using a dry powder inhaler in asthmatics and COPD Source: Eur Respir J 2001; 18: Suppl. 33, 99s Year: 2001
Peak inspiratory flow measured at different inhaler resistances in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020
Inspiratory profiles and consistency of behaviour regarding dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Long acting bronchodilation of Spiriva® handihaler in COPD patients, the influence of the inhalation flow rate (IFR) Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Inspiratory flow rates at different levels of resistance in elderly COPD patients Source: Eur Respir J 2008; 31: 78-83 Year: 2008
Improvements in inspiratory capacity with tiotropium in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 491s Year: 2002
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Source: Eur Respir J 2003; 21: 86-94 Year: 2003
Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Inhaler technique and peak inspiratory flow rates in patients with acute exacerbated COPD Source: Eur Respir J 2007; 30: Suppl. 51, 557s Year: 2007
Inspiratory profiles and resistance of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Low maximum inspiratory flow index in patients with inhaler therapy Source: International Congress 2019 – Nursing care across the spectrum of respiratory illnesses Year: 2019
Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
In vitro delivery of formoterol via a novel multi-dose dry powder inhaler, at clinically relevant inspiratory flow rates Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
In vitro performance characteristics of a novel multi-dose dry powder inhaler Airmax™ at different inspiratory flow rates Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles Source: International Congress 2015 – Lung function: waiting to exhale... Year: 2015